Brain supplement N-PEP-12 shows hints, not proof, on attention

Subjective cognitive complaints, the feeling that your memory or focus has slipped even though formal testing shows nothing wrong, are common in middle-aged and older adults, and may reflect early cognitive changes alongside shifts in stress, mood, sleep and quality of life. There is real appetite for something that helps at this early, pre-clinical stage, and the supplement aisle is happy to oblige. N-PEP-12 is a peptide-based nutritional supplement with claimed neuroprotective potential, but the evidence for it in healthy adults with these complaints has been limited, which is precisely the gap this trial set out to test.

This was a prospective, randomised, double-blind, placebo-controlled trial in which 276 adults aged 50 to 75 with subjective cognitive complaints and no clinically significant impairment were assigned to placebo, N-PEP-12 at 45 mg, or N-PEP-12 at 90 mg. Neither participants nor investigators knew who received what. Assessments ran at baseline and after 30, 90 and 180 days. The primary outcomes were measures from the Test of Attentional Performance; secondary outcomes covered WAIS-IV Digit Span Forward and Backward, perceived stress, mood, sleep quality, and a quality-of-life visual analogue scale.

Across the three primary attention outcomes analysed jointly, there was a significant interaction between group and visit (p = 0.003) and a significant effect of visit (p < 0.001), but no significant main effect of treatment arm (p = 0.133): in plain terms, any benefit depended on when it was measured rather than showing up as a consistent overall advantage. This held in a sensitivity analysis that filled in missing data in the way least favourable to the supplement. Exploratory comparisons at 90 days favoured both doses on alertness, attention omissions and memory omissions, and Digit Span scores also improved. In an uncontrolled extension where everyone received active treatment, former placebo participants improved comparably. Adverse events were infrequent and evenly distributed.

This trial adds a properly controlled study to a thin evidence base, and its size and 180-day length are respectable for the supplement world. But the pattern of results, a time-dependent interaction without an overall treatment effect, plus endpoint gains flagged by the authors themselves as exploratory, places it firmly in the supports-further-investigation category rather than the demonstrated-benefit one. The uncontrolled extension phase cannot carry evidential weight since everyone knew they were on active treatment. Confirmatory trials with the attention gains as pre-specified primary outcomes are what would settle the question.

If you have noticed your focus slipping with age and wondered about supplements marketed for it, this is a reason to hold judgement rather than a reason to buy. The trial's most quotable results are the exploratory ones, and the overall comparison between supplement and placebo did not reach significance. On the reassuring side, side effects were infrequent and no different from placebo. The honest summary is that N-PEP-12 earned itself another study, not a place in anyone's routine.